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 SELECTED ABBREVIATIONS    
 
AASI                   Ambulatory arterial stiffness index 
ABPM                 Ambulatory blood pressure monitoring 
ACEI                   Angiotensin converting enzyme inhibitor 
ARB                    Angiotensin receptor blocker 
ARV                    Average real variability 
BMI                    Body mass index 
BP                       Blood pressure 
BPV                    Blood pressure variability 
DBP                    Diastolic blood pressure 
EGR                    Endogenous glucose release 
ESH                    European Society of Hypertension 
FFA                     Free fatty acids 
GIR                     Glucose infusion rate 
HEC                    Hyperinsulinemic-euglycemic clamp 
HOMA-IR           Homeostasis model assessment, insulin resistance 
IR                        Insulin resistance 
IRS                      Insulin receptor substrate 
IS                         Insulin sensitivity 
MAP                    Mean arterial pressure 
MSNA                 Muscle sympathetic nerve activity 
OGTT                  Oral glucose tolerance test 
PP                        Pulse pressure 
PWV                    Pulse wave velocity 
RDN                    Renal denervation 
RVLM                 Rostral ventrolateral medulla 
RAAS                  Renin angiotensin aldosterone system 
SBP                     Systolic blood pressure 
SCT                     Sham-controlled trial 
SD                       Standard deviation 
SNA                    Sympathetic nerve activity 
SNS                     Sympathetic nervous system 
TRH                    Treatment resistant hypertension 
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Background: Denervation of renal sympathetic nerves (RDN) is a mini-invasive 
endovascular procedure introduced as an antihypertensive treatment with a potentially 
beneficial effect on insulin resistance. In this open-label non-randomized study we 
investigated non-diabetic patients with true treatment-resistant hypertension defined as office 
systolic blood pressure (BP)>140 mmHg and (mean) daytime (ambulatory) BP >135 mmHg, 
despite four or more antihypertensive drugs.  Methods: Bilateral RDN was performed with 
the Symplicity Catheter System (N=23), and patients were followed- for six and 24 months. 
BP measurements were performed after witnessed intake of antihypertensive drugs. BP 
variability and arterial stiffness indices were calculated from 24-hour BP recordings. Insulin 
sensitivity was assessed using a two-step hyperinsulinemic- euglycemic clamp with glucose 
tracer before and six months after RDN. Oral glucose tolerance test, levels of insulin, C-
peptide, adiponectin and leptin were measured and surrogate insulin resistance indices were 
calculated before RDN and during follow-up. Results: Most of the patients were obese, had 
metabolic syndrome and severe insulin resistance at baseline. We found a statistically 
significant reduction of both office and ambulatory 24-hour BP as well as BP variability six 
months after RDN. Despite decline in BP, neither peripheral nor hepatic insulin sensitivity 
improved six months after RDN. Twenty patients continued to the two-year follow up. Some 
rebound in BP was found in most of patients. Arterial stiffness did not change during follow-
up. All measured metabolic variables and insulin resistance surrogate indices remained 
essentially unaltered two years after RDN. Conclusion: Neither peripheral nor hepatic insulin 
sensitivity improved after RDN. Our study does not support the notion of a beneficial 





Arterial hypertension is the most prevalent modifiable risk factor associated with 
cardiovascular events (1). Life style changes and use of several antihypertensive drugs do not 
always result in adequate decrease in blood pressure (BP), a condition defined as treatment 
resistant hypertension (TRH) (2, 3). In addition, high BP may be associated with impaired 
response of tissues to insulin that may lead to type 2 diabetes (4). Both hypertension and 
insulin resistance (IR) are associated with increased activity of the sympathetic nervous 
system (SNS) (5).  
Renal denervation (RDN) is a procedure that aims to destroy sympathetic nerves along renal 
arteries by a radiofrequency catheter inserted through a minimally invasive technique. The 
Re-Shape CV-Risk Study was initiated to test the hypothesis that renal denervation could 
decrease BP and also improve insulin sensitivity (IS) in patients with TRH.  
 BACKGROUND 
 
6.1 Hypertension  
 
Hypertension has become a significant global health burden, and the prevalence is expected to 
increase with aging of the population (6). This is the most important modifiable, preventable 
risk factor for premature death as associated with cardiovascular disease, stroke, type 2 





Hypertension is classified as primary (90% of patients) or secondary if due to other diseases 
as renal failure, endocrine conditions, heart failure, drugs or sleep apnea (8). Primary 
hypertension results from a complex interaction of genes, older age and environmental factors 
including obesity, excessive salt ingestion, smoking and immobility.    
Applying the European Society Hypertension (ESH) guidelines from 2018 hypertension is 
defined as office BP ≥140/90 mmHg (9). Many patients do not have sufficient effect of life 
style changes and medical treatment on their hypertension. This group is defined as patients 
with TRH. Knowing that TRH is associated with increased sympathetic nerve activity (SNA) 
(10), these patients were perceived as a potential target group for therapies able of modulating 
the activity of the autonomous nervous system, such as RDN. According to aforementioned 
guidelines, hypertension is defined as resistant when the recommended treatment (more than 
three different antihypertensive drugs, including a diuretic) strategy fails to lower office 
systolic BP <140 mmHg and/or diastolic <90 mmHg. In addition, TRH is diagnosed by 
ambulatory BP monitoring (ABPM) or home BP measurements, in patients whose adherence 
to therapy has been confirmed. TRH is not synonymous with uncontrolled hypertension, 
which includes patients who lack BP control secondary to poor adherence or inadequate 
treatment. Consequently, true TRH refers to a diagnosis of primary hypertension with 
exclusion of all other potential causes of uncontrolled BP. Although TRH was considered to 
be a common clinical problem, recent research show that exclusion of secondary and pseudo-
resistance hypertension decreases the proportion of patients with true TRH from 40 % (3) to 
10 % (11) of hypertensive patients. Pseudo-resistant hypertension can be caused by different 
factors, such as poor BP measuring technique, white-coat hypertension (12) and poor 
adherence to medication. There are many methods, reported in guidelines, on how to assess 
medical adherence. One of them is witnessed intake of medication.  
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This directly observed therapy followed by ABPM is an easy, available, reliable method to 
control the compliance of patients (13). Providing that they take antihypertensive drugs daily 
this method is safe, though in case of non-adherence, patients need to be observed due to 
potential hypotension complication after taking antihypertensive medications.  
6.1.1 Blood pressure 
 
A careful diagnosis of patients is crucial in selecting true TRH. Whereas classification of 
hypertension and guided treatment is based on office BP, hypertension diagnosed by ABPM 
appears to be a better predictor of organ damage and has been shown to have be associated  
with morbidity and even fatal events (14). In addition, the analysis of 24-hour BP profiles 
provides important insights into the physiological BP regulation and can give us more 
prognostic information than office BP alone. ABPM readings give the possibility to look at 
the BP changes during both day and night. In healthy individuals BP follows a circadian 
pattern, BP starts to decline in the evening, reaches a nadir around midnight and arise fast  
just after awaking in the morning (15). Thus, lowering or “dipping” of the BP during nights is 
a normal physiological variation which can be blunted by the severity of hypertension. A 
worsening of the dipping pattern and high night BP is associated with increased 
cardiovascular risk (16). Furthermore, ABPM give the possibility to assess BP changes during 
the transition from sleep to wakefulness as this period is associated with an increased risk of 
stroke and sudden cardiac arrest (17). Hence, potential effects of interventions that ameliorate 
the sympathetic nervous system should be assessed separately on day-and nighttime BP 




6.1.2 Blood pressure variability 
 
BP is not a constant variable, but it shows spontaneous oscillations over short-term (minutes 
to hours) and long-term (day and month) periods. Short-term BP variability (BPV) is usually 
defined as the oscillation of BP within 24 hours. Fluctuation of BP from minutes to hours 
mainly reflects the influence of central nervous system and autonomic modulation and the 
elastic properties of arteries (18). BPV is the result of complex interactions between extrinsic 
environmental and behavioral factors with intrinsic cardiovascular regulatory mechanisms 
(19). Thus, the reduction of the ability of the arterial and cardiopulmonary reflexes to buffer 
changes in BP can augment short-term BPV.   
BPV increases proportionally to mean BP and seems to contribute independently to the 
presence and severity of target organ damage and cardiovascular events in hypertensive 
patients (20). BPV can be estimated by direct BP measurements or by using mathematical 
calculations, as in the present study. 
6.1.3 Arterial stiffness 
 
One of the main cardiovascular pathophysiologic changes associated with hypertension and 
aging is decrease in large artery compliance, especially in the aorta. The loss of elastic fibers 
in the vessel wall, a concomitant increased collagen deposition and calcification, together 
with an autonomously regulated abnormal arterial smooth muscle tone increases the stiffness 
of the wall. This process is often called “hardening of the arteries” (21). The expression of 
angiotensin type two receptors in vascular tissue leads to vascular wall hypertrophy and 
fibrosis (22). If the elasticity of conductance vessels decreases, diastolic BP (DBP) goes 
down. Then the ejection force cannot be offset by arterial distension, the pulse wave velocity 
(PWV) increases and reflex waves to the heart arrive earlier.  
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That augments systolic BP (SBP), which together with decreasing DBP results in an 
augmentation of the pulse pressure (PP). Then, when excessive PP is transmitted through the 
microcirculation of vital organs such as the brain and kidneys, extensive tissue injury tends to 
occur, leading to increased cardiovascular risk (23). Noninvasive carotid femoral PWV is 
considered the gold standard method for assessing vascular stiffness. This method  is 
recommended by ESH  as a tool for assessment of subclinical target organ damage (9). 
However, Staessen et al. have proposed ambulatory arterial stiffness index (AASI) as a 
surrogate index for arterial stiffness (24). This index is based on the rationale that the 
relationship between SBP and DBP is dynamic, and depends on the functional and structural 
characteristics of large arteries. DBP varies less for a given amount of change in SBP, 
resulting in a lower regression slope and, consequently, in a higher AASI. The stiffer the 
arterial tree, the closer the regression slope and AASI get to 1. 
6.2 Insulin resistance  
 
IR is a condition in which cells are no longer responding appropriately to circulating 
insulin. Since the discovery of insulin over 90 years ago, a wide range of IR definitions and 
explanations of pathogenesis have been applied. First, IR was linked to the observation that 
some of the diabetic patients needed large insulin doses to decrease glucose, secondary to 
antibodies directed against the therapeutic non-human insulin. Second, IR had been associated 
with vascular changes, the hypothesis was that structural and functional changes in the 
vasculature might limit the supply of hormones and substrates to target tissue (25). The 
reduction in the number of open capillaries could increase the distance that insulin must travel 
to reach the muscle cells (26). This might decrease glucose utilization, thereby leading to a 
pre-cellular form of IR.  
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Growing evidence indicates that IR develops mainly because of disturbances within cells, in 
insulin signaling pathways (27). Although the molecular mechanisms are not fully 
understood, one suspects that the strength of the insulin signal from its receptor to its final 
action is attenuated. Insulin affects cells through binding to their receptors on the surface of 
insulin-responsive tissues. The stimulated receptor phosphorylates itself and several 
substrates, including members of the insulin receptor substrate (IRS). Thus, insulin initiating 
down-stream signaling events that leads to control of glucose uptake (28). Insulin, via IRS, 
stimulates the translocation of the glucose transporter (GLUT-4) to the cell membrane, in 
order to bring glucose into the muscle and adipose tissue (29). The inhibition of these down-
stream pathways dysregulates insulin signal transduction within cells causing IR. 
Liver, kidney, skeletal muscle and adipose tissue are the major insulin-sensitive organs 
involved in glucose homeostasis. 
6.2.1 Hepatic insulin resistance 
 
The liver is the first organ to pick up nutrients that enter the body from the intestines and 
plays the role of a ‘glucose-buffering system’. It takes up glucose and stores it in the form of 
glycogen, and releases it back into the blood when blood glucose concentration falls. When 
glucose concentration increases after a meal, insulin is released from  cells in the pancreas to 
the portal system. Glucose is taken into hepatocytes via receptors GLUT-2 independent of 
insulin (30). However, insulin binds to the insulin receptors on the hepatic cells and initiate a 
cascade of enzyme-phosphorylation, leading to activation of glycogen synthesis and reduction 
of gluconeogenesis (31). In the postabsorptive state, the liver is responsible for at least 75% of 
the total endogenous glucose production. In healthy humans, the hepatic glucose production 
rate is around two mg/kg body weight/min (32). The condition where the liver does not 
respond adequately to insulin, is classified as hepatic IR.  
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6.2.2 Peripheral insulin resistance 
 
6.2.2.1 Adipose tissue  
 
Adipose tissue is an active, endocrine tissue that produces adipokines: adiponectin, leptin and 
many proinflammatory cytokines such as TNF- alfa and IL-6 (33, 34). Exposure of cells to 
proinflammatory cytokines stimulates inhibitors of IRS phosphorylation. This is followed by 
attenuation of insulin signaling in insulin sensitive tissue, resulting in IR. Additionally, recent 
studies have revealed that expansion of white adipose tissue in an obese state leads to 
decreased secretion of adiponectin, for which the target organ is the liver. Adiponectin 
receptors in the liver (Adipo R2) reduce gluconeogenesis and free fatty acids (FFA) oxidation. 
Adiponectin directly increases hepatic IS, promotes fuel oxidation in skeletal muscle and 
decreases vascular inflammation. Hypoadiponectinaemia is also known to be consistently 
related to IR, obesity, type 2 diabetes, coronary heart disease, hypertension and 
atherosclerosis, based on both experimental and clinical studies (35).  
Leptin, another important adipokine, was discovered in 1994, and named after the Greek word 
“leptos” meaning thin. Leptin, in opposite to insulin, is a catabolic hormone that increases 
lipolysis in adipocytes and decreases lipogenesis in the liver. However, obese individuals, for 
unknown reasons, become resistant to the satiety and weight-reducing effect of the hormone 
even though they preserve leptin-mediated sympathetic activation to non-thermogenic tissue, 
such as kidney, heart, and adrenal glands. Leptin has also been shown to influence nitric oxide 
production, natriuresis and chronic sympathetic activation, especially in the kidneys (36). 




In the case of overactive SNS or large adipose tissue mass, as in obesity, excess secretion of 
FFA becomes part of an adverse process called lipotoxicity. Overflow of FFA leads to cell 
stress that dysregulates the insulin signaling pathway, not only inside adipose cells, but also in 
other cells (37). FFA that leave the fat cells, enter the circulation and are taken up by other 
organs, such as the liver and skeletal muscle that are unable to safely store large amounts of 
fat. Chronically increased plasma FFA stimulates gluconeogenesis, dysregulate cell pathways, 
and induces hepatic and muscle IR (38). 
6.2.2.2 Skeletal muscle 
 
Skeletal muscle utilizes both FFA and glucose as a fuel to produce energy and these processes 
are regulated by insulin, but also by the SNS. In lean healthy individuals insulin stimulates 
glucose uptake in skeletal muscle and suppress lipolysis. Defects in glucose metabolism in 
skeletal muscle are due to impaired insulin signaling, glucose transport by GLUT4, decreased 
glucose oxidation and impaired glycogen synthesis. One of the suggested explanations is an 
increase in intramyocellular fat content that dysregulates mitochondrial function, what could 
explain that weight reduction correlates with decreased peripheral IR (39, 40). The other, is 
related to inflammatory diseases, where cytokines are supposed to impair insulin signaling in 
skeletal muscle as may be observed e.g. in patients suffering from psoriasis, without being 
obese (41). Thus, skeletal muscle is a key tissue in whole-body energy metabolism and is 






6.2.3 Assessment of insulin sensitivity  
 
While, in many individuals the IR develops simultaneously in multiple organs, the severity of 
IR may differ among the various tissues. Since interventions that may improve IS are organ 
specific (e.g., physical activity for muscle IR, metformin for hepatic IR, and weight reduction 
and thiazolidinediones for both), it is important to quantitate the magnitude of IR separately 
(42, 43). There are many methods and surrogate indices used to asses hepatic and peripheral 
IS, based on fasting glucose and insulin, adipokines or oral glucose tolerance test (OGTT), 
but the gold standard is hyperinsulinemic euglycemic clamping (HEC). It is based on an 
infusion of insulin at a constant rate, while simultaneous infusion of glucose is titrated to 
euglycemia. Although HEC gives a picture of whole body IS, combined with tracer dilution 
method it can separately assess changes in hepatic and peripheral IS (30). A tracer is a 
labelled form of a substance, in this case labelled D-[6,6-2H2] glucose, that makes it 
detectable by liquid chromatography mass spectroscopy.  
6.3 Metabolic syndrome 
 
Hypertension is frequently accompanied by hyperinsulinemia, obesity and IR (4). The central 
hormone involved in this metabolic-BP cross-talk is insulin. As IR develops, more insulin is 
produced by  cells in the pancreas leading to hyperinsulinemia and gradually to type 2 
diabetes. It is well known that fully functional adipose tissue is required for the maintenance 
of normal IS (44). IR is strongly associated with obesity (defined as excess of body fat 
accumulation). That in itself is not necessarily an adverse condition, as long as the fat is safely 
stored in healthy fat cells that respond to insulin. However, fat cells do not have an unlimited 
capacity to expand and dysregulation of fat metabolism plays a pivotal role in the 
development of IR. 
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Metabolic syndrome is a clustering of the aforementioned conditions such as hypertension, 
obesity and IR, all associated with increased cardiovascular risk. According to International  
Diabetes Federation (IDF) definition from 2005, diagnosis of the metabolic syndrome is  
based on central obesity and two other criteria as raised BP, fasting glucose or dyslipidemia 
(45). However, it is still unresolved whether overactivity of the sympathetic nervous system 
accompanied by inflammation, IR and obesity are the cause or an effect of the metabolic 
syndrome.   
6.4 The sympathetic nervous system  
 
The sympathetic nerves are a part of the autonomic nervous system that innervate many 
organs in the human body. Central sympathetic neurons are located in the rostral ventrolateral 
medulla (RVLM), which is a key area for regulation of arterial BP and metabolism (46, 47). 
The RVLM neurons conduct signals directly to the sympathetic preganglionic neurons located 
in the spinal cord that innervate several target organs and thus controlling cardiac output and 
blood flow to skeletal muscles and visceral organs. Feedback information is conveyed by a 
number of afferent inputs from carotid and organ receptors (e.g., mechanoreceptors, 
chemoreceptors) as well as hormonal mediators (48). Postganglionic neurons release the 
primary sympathetic neurotransmitter, noradrenaline. The endogenous natural receptors for 
the catecholamines adrenaline and noradrenaline are adrenergic receptors  and , their 
activations have different effects depending on the target organ.  
Moreover, signals from the brainstem and hypothalamus can also modulate the RVLM 
activation and alter SNA, e.g imidazoline I1 receptor agonist acts centrally at the level of the 
RVLM to inhibit sympathetic drive (49). 
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6.4.1 Regulation of blood pressure  
 
The cross-talk between RVLM and baroreceptors plays a central role in the regulation of BP. 
Sympathetic adrenoreceptors, -receptors, act upon vascular smooth muscle in arterioles, 
leading to vasoconstriction, but 1 receptors in the heart act by increasing cardiac output. 
Thus, low BP sensed by baroreceptors reduces the output of the solitary nucleus, in this case 
stimulating RVLM. This leads to an increase in sympathetic stimulation of the heart and the 
vessels, in order to restore BP. In addition, increased renal sympathetic efferent outflow acts 
by an activation of adrenergic 1receptors in the kidney that releases renin from the 
juxtaglomerular apparatus and stimulates 1 receptors in the nephron tubule to increase 
sodium reabsorption and decrease renal blood flow (50, 51). This sympatho-renal axis 
including both efferent and afferent renal nerves define the dual contribution of the kidney in 
causing hypertension (52).  
BP may be considered as a physiological marker of the autonomic nerve function. Both short 
and long BP fluctuation represents interactions among behavior, environment and neural 
central and peripheral reflexes within the sympathetic and the parasympathetic nervous 
system. In a well-regulated autonomic system, sympathetic withdrawal occurs during sleep, 
leading to a fall in night BP (53). The transition from sleep to awaking is linked to 
sympathetic activation and gain in plasma catecholamines which results in increased BP and 
heart rate. The mechanisms responsible for day-night BP changes are still not clear. 
Exaggerated BP responses to standing might be associated with increased basal SNA (54). In 
hypertension and obesity sympathetic outflow to skeletal muscle and kidney is increased  
contributing to continuous dysregulation in circadian BP pattern (55). Notably, an 




6.4.2 Regulation of metabolism 
 
The SNS plays an important role in regulation of daily energy expenditure by controlling of 
metabolic rate, food intake and temperature. It has been generally recognized that increased 
SNA produces catabolic effects on glucose and lipid metabolism whereas increased 
parasympathetic neural activity produces anabolic effects.  
A number of afferent nerves from peripheral organs convey metabolic information that 
modulate activation of RVLM. Circulating factors such as insulin and angiotensin, which are 
able to cross the blood-brain barrier and have receptors distributed throughout the brain, can 
influence central sympathetic outflow and thereby modulate peripheral lipid and glucose 
metabolism (56). Leptin receptors are not only presented in the hypothalamus, but also in the 
solitary nucleus, contributing to SNA (57). Norepinephrine from sympathetic nerves and 
epinephrine released from the adrenal medulla affect glucose transport and metabolism in 
liver, pancreas, adipose tissue, and skeletal muscle. The liver, which plays a key role in 
glucose metabolism, is richly innervated by the autonomic components from the splanchnic 
sympathetic nerves and vagal parasympathetic nerves. Additionally, the part of sympathetic 
nerve fibers which innervate the liver arise directly from the hypothalamus - a center for the 
food intake and appetite regulation (58). SNA and catecholamines increase glucose by 
activation of 1 and 2 receptors in the liver that leads to glycogenolysis and 
gluconeogenesis.  
The sympathetic nerves innervating skeletal muscle can modulate glucose uptake and 
glycogenolysis independent of concomitant increase in plasma insulin levels, via activation of 
2 adrenergic receptors (59, 60). Of note, administering a medical β2 agonist appears to 
improve glucose tolerance due to increased glucose uptake in skeletal muscle (61). 
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Conversely, neuronal stimulation of -adrenergic receptors in arterioles, elicits 
vasoconstriction. Thus, reduction in the number of open capillaries may decrease glucose 
utilization leading to peripheral IR. 
Compared to the liver, pancreas, and skeletal muscle (which are also under parasympathetic 
control), adipose tissue is only innervated by sympathetic nerves making the SNS an 
important regulator of lipid mobilization. The SNS stimulates adipocytes by 1-3 receptors, to 
increase lipolysis and to produce FFA (62, 63). 
All these processes increase BP and glucose concentration in the blood, actions that are 
expected after activation of the SNS to protect vital organs and activate the body in case of 
danger. However, overactivity of the SNS, due to chronic increase of stimulating factors or 
decreased activation of the parasympathetic system, contributes to the development of many 








Figure 1. Role of central sympathetic nerve activation in BP control, glucose and lipid 
metabolism 
 
IR-insulin resistance, BP-blood pressure, HR-heart rate, RAAS-renin-angiotensin-aldosterone system, EGR-endogenous 
glucose release, FFA- free fatty acids, GLUT-4-glucose receptor 
 
6.5 The rationale for renal sympathetic denervation   
The renal sympathetic nerves run along the renal arteries in the adventitia. Afferent fibers 
from the kidneys convey signals to the brain, to regulate whole body sympathetic tone that 
contributes to the neurogenic mechanism of hypertension (48, 64). Renal efferent nerves 
innervate the kidneys from the para-vertebral ganglia at T11-L3, mediate in renal sodium 
retention (65) and stimulate the neuro-humoral renin-angiotensin-aldosterone axis. Knowing 
that BP depends primarily on neural control and volume regulation, sympathetic nerves plays 
an important role in BP regulation.  
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Thus, surgical thoracolumbar sympathectomy, resulting in renal denervation, was performed 
during the first half of the 20th century to treat malignant hypertension. The technique resulted 
in effective BP reduction. It was, however, accompanied by postural hypotension, erectile 
dysfunction and syncope (66, 67). Therefore, later availability of effective antihypertensive 
drugs put surgical antihypertension treatment aside. Despite a variety of antihypertensive 
drugs and combination of those, as well as resources to assist patients’ adherence and lifestyle 
changes, BP and cardiovascular risk did not decrease in all patients, as expected. In the light 
of the development of invasive radiology and cardiology, the idea of a non-surgical 
sympathetic denervation emerged. Based on the anatomical availability of the renal nerves 
from a femoral access (via a 6F introducer through common femoral artery to the renal 
arteries) and given that efferent and afferent renal sympathetic nerve overactivity is thought to 
contribute to hypertension development, RDN has been developed to target these pathways to 
reduce BP. There are several types of RDN devices using different types of energy or 
chemical substances to damage nerves. Radiofrequency energy transform electrical current to 
high temperature resulting in localized tissue destruction and has been used in cardiology for 
many years to treat arrhythmias. RDN is a mini-invasive procedure using specialized 
radiofrequency ablation catheter with access to the renal arteries from one of the femoral 
arteries. The first-generation radiofrequency ablation catheters as Ardian system (Figure 2) 
applied usually, four to six two-minute treatments per renal artery to damage renal nerve 
fibers. The later evolution of RDN multielectrode devices led to an increased number of 







Figure 2. Nerve fibers along the renal artery and the Symplicity radiofrequency flex 
catheter  
 
Picture of the Ardian system, with permission from Medtronic 
The first RDN studies including SYMPLICITY HTN-1 and 2, demonstrated a significant 
reduction in BP after RDN (68, 69). Catheter-RDN has emerged as a new approach for TRH. 
Several studies have shown that RDN lowered SNA (as assessed by renal noradrenaline 
spillover) (68, 70), and muscle sympathetic nerve activity (MSNA) (71). Other RDN trials 
focused on an additional potential RDN effect on heart arrhythmias (72) and glucose 
metabolism (73). However, the publication of the SYMPLICITY HTN-3 changed the view of 
RDN research (74). This blinded trial did not show significant reduction in BP in patients 
with TRH six months after RDN, as compared with a sham control group. In the RDN group 
mean SBP measured in the office was reduced by an average of 14.1  24 mmHg, whereas 
the corresponding SBP decline in the sham-controlled group was 11.7  26 mmHg. Moreover, 
mean 24-hour SBP showed no significant between-group differences six months after the 
procedure. However, no drug adherence control and operator inexperience were major 





In the later years RDN studies have focused on renal artery microanatomy, and identification 
of response based on renal nerve stimulation (75). Of note, proof of principle for the BP 
lowering effect of RDN have been demonstrated in some new, sham-controlled trials (SCT), 
even though the BT reduction was modest. These studies differed from previous RDN trials 
regarding patient selection, procedural and operator related aspects (76-78). 
Due to the complex interactions between hypertension and IR it is difficult to indicate the 
primary insult that leads to overactivation of the SNS. This sympathetic cross-talk between 
the kidneys, peripheral tissue and the brain appears to play an important role in TRH and IR. 
Advances in technology and the availability of mini-invasive procedures as catheter-based 














 AIMS OF THE THESIS 
 
The general aim of this thesis was to study the intraindividual changes in glucose metabolism 
after RDN, a new invasive method, applied in patients with TRH. The first step was to study 
BP and BPV change six months after RDN. Further, we wanted to test the hypothesis that IS, 
measured using the gold standard method, HEC, may be improved six months after RDN.  
Finally, we wanted to evaluate whether progression in IS might be delayed or even reversed at 
two-year follow-up after RDN, and whether changes in IS may be related to BP and arterial 















8.1 Ethical approval 
 
The study was conducted in accordance with the protocol, applicable regulatory requirements 
and the ethical principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal 
Regulations, Part 46, Protection of Human Subjects, Revised 13 November 2001, effective 13 
December 2001. The Regional Committee for Medical and Health Research Ethics as well as 
the Data Protection Officer at University Hospital of North Norway gave their approval. The 
included patients gave their written, informed consent. ClinicalTrials.gov 
Identifier:  NCT01630928). All authors were funded by governmental nonprofit organizations 
in Norway. The study was supported by The Norwegian Diabetes Association, The North 
Norwegian Health authorities and UiT The Arctic University of Norway. The study also 
received an unrestricted grant from Medtronic. The funders had no access to the study data, 
and had no role in the design, conduct or reporting of the study. 
8.2 Study population 
 
Patients with TRH, classified according to a modified definition from the 2007 ESH 
guidelines (79) and confirmed by ABPM followed by hypertension specialists were eligible 
for inclusion in this study. The study was performed from 2013 to 2015. The patients had 
office BP >140/90 mmHg and were treated with four or more antihypertensive drugs, 
including a diuretic, in maximally tolerated doses. In addition, subjects had to have an 
average daytime SBP 135 mmHg, as measured by ABPM after an investigator witnessed the 
intake of their antihypertensive drugs. The antihypertensive medications were kept unchanged 
at least 14 days before starting the study.  
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Before being accepted as candidates for inclusion, secondary hypertension was excluded by 
standard clinical evaluation, and blood tests including measurements of serum aldosterone, 
thyroidal hormones, renin activity, normetanephrine and metanephrine. Exclusions criteria 
were as follow: <18 age > 68 years old, estimated Glomerular Filtration Rate (GFR)< 45 
mL/min/1.73m² after MDRD formula (Modification of Diet in Renal Disease) (80), a 
previous diagnosis of diabetes, hemoglobin A1c (HBA1c)  6,5%, hemodynamically 
significant heart valve diseases, implanted pacemaker, contrast allergy, cancer last five years, 
pregnancy, previous renal transplantation, renal artery anatomy factors like diameter less than 
four mm, length <20mm (measured from ostium to first major side branch), renal artery 
stenosis or significant  atherosclerosis and previous renal stenting. To achieve the power 
needed for the primary endpoint (20% change in basal EGR), 20-25 patients were needed. 
Twenty-three patients with TRH were included in the study and underwent RDN.  
Figure 3. Flow chart of the present study 
 
Specialist referrals from 
outpatient clinic (n=26)
Patients excluded by qulification  
process 
A. daytime <135 mmHg(n=2)
B. renal artery abnormality (n=1)
23 patients were included  
and treated by RDN 
At 6-month follow-up:
(3 patients did not complete clamp due to technical  
problems)
20 patients available with clamp data,
23 with BP data
At 24-month follow-up:
(2 patients withdrew,1 died, 1 startet with antidiabetic 
drugs)
20 patients available with BP data
19 with metabolic data
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8.3 Measurements of blood pressure indices 
 
8.3.1 Blood pressure  
 
Patients were asked to bring their prescribed medication in original package to the clinical 
visit with one of the study nurses. Medication was documented, administered by the nurse and 
swallowed by the patient under continuous observation, to secure intake of the medication in 
prescribed doses. Patients were then continuously under observation by the nurse until 24- 
hour ABPM device had been mounted and tested. Information about lifestyle was assessed by 
a self-administered questionnaire. Medical history was taken by one of the study physicians. 
Patients were asked about obstructive sleep apnea symptoms, physical activity, diet and 
smoking. Changes of the antihypertensive medication was not allowed during the study, 
unless judged medically necessary. 
ABPM readings were taken every 20 minutes during daytime (7:0 AM to 10:0 PM), and 
every 30 minutes during nighttime (10:0 PM to 7:0 AM).  
Nocturnal hypertension was defined as (mean SBP ≥ 120 mmHg) (9). Mean arterial pressure 
(MAP) was calculated as [(2 × DBP) + SBP]/3 from ABPM. The degree of nocturnal BP fall 
(dip %) was calculated as 100 x (1- (average of nighttime BP/average of daytime BP)). 
Patients with nocturnal BP reduction less than 10 percent was defined as non-dippers.  
Participants were classified as BP responders if they achieved a reduction in mean 24-h SBP 




Only ABPM with qualified recordings covering more than 70% of the 24 hours were regarded 
as technically sufficient for inclusion in the analyses. From the ABPM recordings, mean 24-
hour SBP and DBP were computed. Office BP readings were taken in a seated position with 
an automatic oscillometric device after five minutes of rest. BP was measured on each arm, 
and the arm with the higher BP was used for all subsequent readings.  
Averages of the two last measures were calculated and used for analysis. The same 
experienced nurses handled all BP measurements using the same calibrated devices in all 
patients at baseline and at follow-up. Office BP readings were taken by Casmed 740, (Infiniti 
Medical AS, USA) and ABPM was assessed using Schiller BR-102 plus (Diacor AS, 
Switzerland). 
8.3.2  Blood pressure variability  
 
Ambulatory BP recordings were analyzed and the standard deviation (SD) of 24-hour BP as 
well as SD of day and nighttime was calculated. Knowing that nocturnal BP fall is 
significantly and positively related to 24-hour BP SD, we assessed the weighted standard 
deviation (wSD) for each period of the day, to remove the mathematical interference from 
nighttime BP fall. We calculated wSD of SBP and DBP as the average of daytime and night 
time SD, divided by the duration of the day and night periods, respectively (82).  
Current evidence suggests that average real variability index (ARV) adds significant 
prognostic information to ABPM monitoring, thus we calculated ARV as previously reported 
(83).  
Morning BP surge was calculated as the difference between the average of SBP during two 
hours immediately after awakening and the average of the three SBP readings centered 
around the lowest night SBP value (after crosschecking the patients diary) (84).  
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The two-hour awake BP was defined as the average of four-five BP readings during the first 
two hours after morning arousal. The coefficient of variation of SBP and DBP was assessed 
by dividing SD by mean SBP and DBP, to examine whether the effect of BPV was 
independent of the BP level (85).  
8.3.3 Arterial stiffness 
PP was calculated as differences between mean systolic and diastolic ABPM. AASI, a 
surrogate measure of arterial stiffness, was calculated from ABPM readings as one minus the 
regression slope of DBP on SBP (24). 
8.4 Assessment of metabolic variables and insulin sensitivity 
 
8.4.1 Metabolic variables 
 
From creatinine measurements eGFR was calculated using the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation (86).  
Metabolic syndrome was diagnosed according to the IDF criteria from 2006 (45).  
According to the American Diabetes Association criteria individuals were classified as having 
normal fasting glucose and tolerance, impaired fasting glucose or impaired glucose tolerance 
(87). Venous blood samples were drawn after an overnight fast (12 hours).  
A standard (82.5 g of glucose monohydrate) OGTT was performed, with plasma samples 
obtained at 0, 30, 60, 90, and 120 minutes after the glucose load. Postload glucose and insulin 
responses were calculated as incremental area units during the two-hour sampling time, and 
were expressed as the area under the curve (AUC) for glucose and insulin.  
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Insulin (endogenous and lispro) during HEC was measured with radioimmunoassay. Levels 
of insulin during the OGTT and C-peptide were measured by ELISA (EIA-1293 and EIA-
2935 respectively; AH Diagnostics, Aarhus, Denmark). ELISA was used also to analyze 
leptin (EIA-2395), adiponectin (Acrp30). 
8.4.2 Clamp procedure  
 
Two step-HEC was performed after a 12-hour fast, as previously described (88). After the 
drawing of fasting blood samples, a primed (3 mg/kg/5 min), continuous (2.4 mg/kg/h) 
infusion of D-[6,6-2H2] glucose was performed for 150 min. to assess basal non-insulin 
stimulated endogenous glucose release (EGR) and whole-body glucose disposal (WGD). 
Tracer infusion was then continued, and a primed (127 mU/m2/min for 10 min) infusion of 
human insulin (insulin lispro) was commenced at low (13 mU/m2/min) and then high dose 
(40 mU/m2/min), each lasting 120min. Glucose (200 mg/mL) enriched with D-[6,6-2H2] 
glucose at a 1.25 atom percent enrichment to improve the sensitivity of the method, so-called 
hot-GINF, was variably infused during the step-clamp to maintain normoglycemia (5 
mmol/L).  
Glucose in arterialized blood was measured every five minutes during the step-clamp. From 
fasting blood samples glucose, insulin and C-peptide were measured. From basal sample and 
at every steady-state (last 40 minutes of step) new blood samples were obtained for insulin, 
C-peptide and tracer measurements. Sampling, chemical analysis, and the determination of 
tracer enrichment were performed as previously described, using liquid chromatography mass 




Figure 4. Schematic illustration of HEC 
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Whole-body IS was expressed as the glucose infusion rate (GIR) (mg/kg/min) during the last 
40 min of each step of the clamp (steady state). The IS index (ISI) was calculated as the mean 
GIR divided by the mean insulin concentration at each step. Total glucose rate of appearance 
(Ra) and WGD as rate of disappearance (Rd) were calculated using modified versions of 
Steele’s equations for non-steady state before step 1 (90, 91). 
                                          Tracer infusion          2.4mg/kg/h 
 























Figure 5. Ra and WGD calculations 
 
F: the tracer infusion rate;                    E: the tracer enrichment;      p: the pool fraction (0.65); 
V: volume of compartment, the distribution volume of glucose taken as 230 ml/kg;   
C: glucose concentration;                     C*: plasma tracer concentration;  
Rd: rate of glucose disappearance;       Rd*: rate of tracer disappearance;  
Ra: rate of appearance;                         Ra*: tracer infusion rate; 
F -consisted of the continuous tracer infusion alone prior to clamping, as opposed to during 
clamping where F was the sum of the continuous tracer infusion and tracer infused with the 
labelled glucose infusate during the last 40 min of each clamp. A linear curve was fit to the 
glucose concentration and tracer enrichment raw data by linear regression in order to 
minimize analytical variation and improve accuracy of the calculations.  
EGR was calculated by subtracting the rate of exogenous GIR from the Ra of labeled glucose 
(EGR=Ra-GIR).  
The following calibrated infusion pumps were applied: care fusion Alaris Guardrails (BD, 
San Diego, CA) syringe pumps were used for insulin, and infusions of D-[6,6-2H2] glucose 





8.4.3 Surrogate insulin resistance indices   
 
1. Homeostasis model assessment (HOMA-IR) = (fasting glucose [mmol/L] x fasting insulin 
[μIU/mL]/22.5) (92).  
2. Quantitative IS Check Index (QUICKI) =1/(log [fasting glucose (mg/dL)]) + log(fasting 
insulin [μIU/mL] (93). 
3.Simple Index Assessing IS OGTT (SIisOGTT) 1/(log [ glucose t 0–30–90–120] [mmol/L] 
+ log [ insulin t 0–30–90–120] [μIU/mL]) (94).  
4. The triglyceride and glucose (TyG )= Ln [fasting triglyceride (mg/dL) x fasting glucose 
(mg/dL) /2] (95).  
5. The leptin-to-adiponectin (LAR) index-was calculated by dividing serum concentrations of 
fasting leptin (ng/ml) by fasting adiponectin (μg/ml)] (96).  
6.The HOMA-adiponectin model assessment (HOMA-AD) was calculated with the formula: 









8.5 The renal denervation procedure 
 
RDN was performed with transfemoral access using the Symplicity Catheter System 
(Medtronic, Mountain View, CA), which was the first commercially available system used for 
RDN. Immediately before the procedure, renal anatomy was clarified using renal 
angiography, if not done before with computed tomography. The main trunk diameter should 
be more than four mm and length more than 20 mm. RDN procedure was performed via 
femoral artery catheterization with 6F catheter. After the cannulation of the artery, 5000 units 
of heparin were administered for anticoagulation. Then the flexible radiofrequency catheter 
was advanced into each renal artery under fluoroscopic guidance with the tip of the catheter 
placed in the ostium of the renal artery. The Symplicity catheter consists of a unipolar 
ablation catheter and a proprietary low-energy radiofrequency generator. Radiofrequency 
works by an alternating electrical current system (five to eight Watts) via a single electrode 
catheter with electrode tip size of two mm, that heats the tissue in contact with the catheter tip 
(up to four mm depth) and by thermal conduction (50-70 °C) to deeper tissue (98). 
Radiofrequency energy is applied to the endothelial lining, delivered energy causes local 
thermal destruction in the perivascular adventitia expecting to damage sympathetic nerves 
lying there. Native renal blood flow cools the intima and reduce endothelial injury. Between 
the ablations the catheter was drawn back one to two mm, rotated a little before another 
ablation was applied, to get a helical pattern of ablations to cover the circumference. 
Accessory branches were not denervated. This procedure was repeated four to five times 
before the same procedure was performed in the other renal artery. On average, each patient 
had 12 ablations of two minutes duration and the minimum number of complete ablations per 
side was more than four, as performed in other SYMPLICITY studies (69). The procedure 
duration was 50 to 90 minutes.  
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In case of a sudden rise in impedance, which could suggest overheating of radiofrequency 
catheters, the auto-feedback mechanisms prevented excessive temperature elevations. RDN 
was performed by one, experienced interventional cardiologist trained for the procedure 
(TKS). A product manager from the manufacturer (Medtronic) were present following all 
steps in the procedure for all patients. The perivascular neural bundle also contains sensory C 
fibers and thus neural destruction is accompanied by significant pain. Intraprocedural pain 
was managed with intravenous anxiolytics and narcotics (midazolam and morphine). Patients 
were hospitalized overnight and followed with self-administered BP measurements at home 
weekly the first month, later monthly, after written and practical instruction. After the 
procedure, all patients received Aspirin or Clopidogrel for at least one month. Six months and 
two years after the procedure all patients came for a follow-up visit with office BP and 
ABPM measurements after witnessed intake of medicines, as described above.  
 
8.6 Statistical analysis and power calculation 
  
Data were presented as mean ± SD if normally distributed or as median (min, max) if skewed. 
For continuous variables, we used paired Student’s t-tests to compare differences between 
pre-RDN and six-month follow-up measurements and between pre-RDN and two-year 
follow-up. For variables with a skewed distribution we applied Wilcoxon signed-rank tests. 
Correlations were assessed using Pearson`s test. Statistical analyses were performed using 
SPSS software (IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0. 
Armonk, NY: IBM Corp.). Differences were considered statistically significant at p<0.05. 
A 20% change in basal EGR (0.4 mg/kg/min) was considered to be clinically relevant. With 
an a level of 0.05 and a power of 80%, 20–25 patients were needed to demonstrate a 20% 
difference in basal EGR before and after intervention (99). 
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 SUMMARY OF RESULTS 
 
9.1 Paper I 
 
In paper I we assessed the change in BP and short-term BPV from baseline to six months after 
RDN. Bilateral RDN was performed in 23 patients (mean age was 53 ± 8 years) without any 
periprocedural or late complications up to six months. The number of ablations for each 
patient were 12.6 ± 2. At baseline all patients used a diuretic and an angiotensin converting 
enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB), 87% of patients used a 
calcium channel blocker, 48 % of patients used an aldosterone antagonist, minimum 25mg 
daily. The office SBP and ABPM fell significantly from 162 ± 20 mmHg to 139 ± 19 mmHg 
(p=0.001) and from 154 ± 20 mmHg to 144 ± 16 mmHg (p= 0.038) respectively. Reductions 
in office and ambulatory DBP were also significant. There was a statistically significant 
reduction in both systolic and diastolic mean and daytime BP, but not in nighttime SBP. We 
observed a reduction in office SBP ≥ 10 mmHg in 13 out of 23 patients and, accordingly, a 
decrease of mean 24-hour SBP more than five mmHg was seen in 12 of 23 patients (52%). 
There was a significant reduction in the number of prescribed drugs from a mean 4.8 to 4.2 
(p=0.02). Heart rate did not change significantly from baseline (72 ± 12 beats per minute) to 
six months control (72 ± 12 beats per minute). Body mass index (BMI) and eGFR remained 
stable during the study.   
BPV measured as SD of 24-hour BP as well as SD of daytime BP fell significantly from 
baseline to six months, whereas no significant change in SD during nighttime was found. 
Significant decrease of both systolic and diastolic wSD and ARV was found after six months. 
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The morning BP surge and the two-hour awake BP decreased significantly from 29  13 
mmHg to 20  14 mmHg (p=0.011) and from 157  19 mmHg to 147  16 mmHg (p=0.024) 
after six months. Systolic and diastolic dipping did not change significantly.  
9.2 Paper II  
 
In paper II, we assessed whether IS improved six months after RDN. Twenty-one of 23 
patients had central obesity, and 18 patients had metabolic syndrome at baseline. Fifteen 
patients had normal fasting glycemia, eight patients had impaired fasting glycemia, and 17 
patients had impaired glucose tolerance. Fasting plasma glucose and the OGTT-derived AUC 
for glucose and insulin remained unchanged at six-month follow-up-Figure 6.  





High insulin and C-peptide concentrations were seen at baseline and remained unchanged 
after six months. Accordingly, the indirect indices of IR, QUICKI, SIisOGTT, and HOMA-IR 
were high at baseline and did not improve after RDN. Twenty-three patients were scheduled 
for a two-step HEC with glucose tracer and labeled glucose infusion before and six months 
after RDN. Three patients were excluded from the clamp measurements because of technical 
problems encountered during the clamp procedure. Basal EGR and WGD measured by 
glucose tracer infusion did not change significantly after RDN (2.12  0.36 mg/kg/min vs. 
2.15  0.41 mg/kg/min (p=0.34), and 2.20  0.36 mg/kg/min vs. 2.14  0.40 mg/kg/min 
(p=0.35), respectively. During the two-step HEC, no significant changes in GIR and ISI were 
seen, indicating unaltered whole-body IS. Fasting and steady-state plasma C-peptide and 
insulin levels during the clamp remained unaltered after RDN.  
The suppression of EGR decreased significant during low-dose insulin infusion, but remained 
unchanged during high-dose insulin infusion. The increase in WGD during high-dose insulin 
infusion was modest and remained unaltered at follow-up as presented below in Figure 7. 
Figure 7. Change of EGR and WGD during two-step clamp before and six months 
after RDN 
 
No improvement in IS was observed in a subanalysis of nine patients with extensive systolic 
mean ambulatory BP reduction (>10 mmHg) after RDN.  
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9.3 Paper III 
 
We wanted to evaluate IR, adipokine profiles, BP and arterial stiffness changes two years 
after RDN. We also studied the correlation between gold standard measurements of IS and 
surrogate indices in this cohort of patients with TRH. Twenty patients continued to two-year 
follow-up (18/20 were men). There was a small, no significant reduction in the number of 
antihypertensive drugs from a median of 4.5 (4-8) different drug classes before RDN to 4.0 
(0-7) (p=0.08) two years after RDN. Nocturnal hypertension was observed in 16 patients at 
baseline and 18 at two-year follow-up. Sustained reduction in DBP and MAP, but not SBP, 
was found two years after RDN. PP and AASI did not change significantly during follow-up. 
After two years two patients had developed type 2 diabetes. One of them received antidiabetic 
treatment at two years and was excluded from the two-year metabolic calculations. We found 
a borderline increase in BMI from 31.6 to 32.6 kg/m2, p=0.05. Most of the metabolic 
parameters or IR surrogate indices were essentially unchanged two years after RDN, apart 
from a statistically significant increase in HOMA-AD and QUICKI indices, however, with 
vague clinical relevance.  
There were no significant changes in the adipokines during the two-year study period.  
There was modest correlation of the different indices of IR and HEC measurements prior to 
RDN. Peak of glucose concentration at 30 minutes during OGTT (OGTT 30 min.) correlated 
best with EGR reduction during low-dose insulin infusion. HOMA-IR correlated best with 
GIR and WGD increase during high-dose insulin infusion. Other indices, including TyG, 
LAR, C-peptide, adiponectin and leptin, correlated neither with hepatic nor peripheral clamp 
derived IS measurements. BP responders and non-responders did not show statistically 
different hepatic or peripheral IR prior to RDN.  
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There were no significant correlations between IR, adipokines, BP or AASI throughout two 
years of follow-up. As reported in Paper II, we found a statistically significant deterioration of 
hepatic IR six months after RDN. Nocturnal systolic BP and arterial stiffness before RDN 
correlated positively with a progression in hepatic IR at six-months follow-up. 
Figure 8. Change in mean systolic ABPM from baseline to two-year follow-up relative 
to drug adjustment. 
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  METHODOLOGICAL CONSIDERATIONS 
 
Participation in the study did not expose the patients to unacceptable risk. The benefits of a 
potential BP reduction outweighed the possible harm of the RDN and clamp procedures. The 
patients were carefully followed-up and received information about individual results at the 
end of the study.   
10.1 Renal denervation 
 
Efficacy 
After the initial studies on RDN subsequent studies in the field suggested that the distribution 
pattern, density and distance to the lumen of the renal sympathetic nerves vary in animals and 
humans, hence this may have impact on the success of RDN (100, 101). 
Starting the Re-Shape study in 2013, we applied the equipment that was available, the 
Symplicity Flex catheter. RDN was recommended to commence distally and to be performed 
by pulling and rotating the catheter tip to obtain a helical pattern of ablations. The procedure 
was performed empirically, as there is no intraprocedural test available to assess denervation 
effect. Given the spiral course of the nerve bundles, a nerve might cross to another quadrant 
between the ablation points and escape denervation. The manipulation of the Symplicity Flex 
catheter to achieve adequate contact and a circumferential ablation pattern is technically 
challenging, and thus requires rigorous training and great operator experience. Even though in 
our study the procedure was performed by one experienced interventional cardiologist (who 
participated in more than 20 RDN procedures in a specialized center in Germany, before 
treatment of the study patients) we cannot guarantee sufficient denervation in every patient. 
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Further research has brought new information, demonstrating that sympathetic nerves may 
not form a true renal plexus surrounding the proximal or ostial vessel segments which were 
focus in the first generation RDN trials (102). Many human studies have revealed that in a 
large percentage of kidneys, the main renal artery divide into many branches from the hilum 
and some nerves commonly bypasses from the preaortic ganglia to the branches (jumping 
over the main renal artery) (103). Other findings suggest that additional denervation of the 
distal artery and associated branches may contribute to better RDN effect (70). This is crucial, 
because in Re-Shape study, only the main artery was treated. Thus, we cannot exclude that in 
some patients, we could have missed some renal nerves.  
For a successful RDN, an accurate depth of the lesion is essential to sufficiently damage the 
periarterial nerves (104, 105). The Symplicity Flex catheter applies low energy and deliver 
about eight watts, which heats the tissue up to about four millimeters depth (98). Evolving 
evidence indicate that in human renal arteries, a substantial number of renal sympathetic 
nerves are located out of reach of the standard lesion depth delivered by radiofrequency 
catheters (100). Moreover, radiofrequency energy can be deflected by tendons and lymph 
nodes, adjacent to the renal arteries. 
It also seems reasonable that a larger number of ablation points may increase the probability 
of adequately denervation of the kidney. In the newer RDN studies, spiral multi-electrode 
catheters were used. These new catheters may help to achieve complete circumferential nerve 
ablation, as the catheter does not need to be re-positioned between energy applications. The 
total number of ablations per patient, performed in our study, was 12, compared to 
SYMPLICITY HTN-1,2,3 with 7-8, 8-12, 13 ablations, respectively (68, 69, 74). However, 
applying multi-electrode catheter in SPYRAL HTN-OFF/ON MED trials the number of (main 
vessel and branches) ablations per patient was 44/46, respectively (77, 78).  
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Albeit, Lauder et al. showed, that ambulatory BP lowering was not related to renal artery 
length nor increasing number of ablations (106). 
Indeed, it is still a matter of debate, what quantity of renal sympathetic nerves need to be 
ablated to achieve significant clinical results. It has been suggested from animal experiments 
that more than 50% of the periarterial renal nerves should be damaged to expect alterations in 
norepinephrine contents in the kidney (104). Given that the SNS induces different responses 
in many organs, the outcome of RDN cannot be limited to the evaluation of the one 
parameter. One of the major limitations of the available techniques is that there is no 
intraprocedural tests to assess proper ablation and effective destruction of the renal 
sympathetic nerves. In compliance with most RDN studies we did not measure SNA changes 
before and after RDN as there is still no good method to assess the procedural endpoint or the 
completeness of RDN. Summing up, the effectiveness of RDN procedure is unknown and 
new data make us question whether the Symplicity Flex catheter might be able to adequately 
ablate renal nerves. Thus, performance bias cannot be eliminated.    
Durability 
The durability of sympathetic modulation by RDN is an unanswered question, where nerve 
regeneration and cross-talk between denervated kidneys each may play a role (107, 108).  
Most of the patients that underwent surgical sympathectomy exhibited no rebound in BP over 
ten years (67). Albeit, only reports from animal research are available concerning the 
destruction and regrowth of renal nerves after RDN (109-112). The assertion about sustained 
BP reduction is mainly based on data from RDN registries which have shown a consistent BP 
reduction, both systolic and diastolic, even after three years (113, 114). However, a potential 
impact on BP results by improved adherence to antihypertensive treatment and patient’s 




In our study, RDN was performed without any early complications. One patient experienced 
short-term orthostatic hypotension, but none of the patients experienced a hypertensive crisis 
or acute kidney injury. During the long-term follow-up, one patient died for unknown reasons 
two years after RDN. Due to the study design, we did not perform imaging of renal arteries 
after the RDN procedure, even in the patients who had experienced BP gain. However, a 
recent meta-analysis of 50 RDN trials including over 5700 patients with median follow-up of 
11 months, estimated the incidence of new renal artery stenosis leading to revascularization to 
be 0.2% per year (115). In the longest follow-up study so far, presented by the Oslo RDN 
study, no renal stenosis has been revealed up to seven years after RDN (116). We limited 
safety control to the assessment of the kidney function, which was stable during two years of 
follow-up (117).  
10.2 Clamp 
 
The preceding studies that reported improvements in IS after RDN calculated changes in IS 
using surrogate indices with variable accuracy compared to the gold standard method. The 
two-step HEC with infusion of glucose tracer remains the only reliable noninvasive method to 
separately assess hepatic and peripheral IS. However, although considered gold standard 
method, some limitations of our clamp results must be revealed.  
We did not measure glucagon, the major hormone that opposes the effects of insulin on 
hepatic glucose metabolism, functioning as a positive regulator of gluconeogenesis and 
glycogenolysis. SNA plays an important role in metabolic alterations, but via different 
pathways. Moreover, we did not assess FFA change during insulin infusion, which could 
contribute to whole body IS.  
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An evaluation of adipose tissue activity should not be limited only to adipokines, especially in 
case of an unequal gender distribution, as in our study (118). This is commented on in Paper 
III. 
EGR was calculated as described above, and it should be taken into consideration that the 
liver is not the only glucose-producing organ during fasting conditions. The kidney cortex 
produces glucose by gluconeogenesis, and its relative contribution to EGR in the 
postabsorptive state is estimated to range from 5 % to 28 % (119, 120). Since the RDN 
intervention is performed directly on the kidneys, local changes in renal glucose metabolism 
could occur. Given that catecholamines and insulin play a role in the regulation of renal 
glucose release, as well as glucose reabsorption, this could have affected the results.  
10.3 Blood pressure 
 
The publication of the first RDN results in 2009 was met with a huge enthusiasm and 
thereafter many studies presented strong BP reductions after RDN procedures. Most of these 
trials lacked a sham-controlled group, and strict patient selection and control of adherence to 
medical treatment was not an issue. We used strict criteria related to both the number of 
prescribed drugs and daytime ABPM. Although the 2007 ESH guidelines did not require 
ABPM to diagnose TRH, we chose to exclude subjects having an average daytime SBP of 
<135 mmHg.  
This was important, since ABPM appears to be associated with cardiovascular events (121). 
Another strength of our work was that secondary hypertension was carefully ruled out before 




The patients’ adherence to medical treatment was also an issue of utmost importance. To 
exclude nonadherent patients, we chose one of the methods recommended by guidelines, i.e. 
investigator witnessed intake of medications, proposed by the researches from the Oslo RDN 
study (13). In our study, none of the patients experienced hypotension after witnessed intake 
of their prescribed antihypertensive drugs. Only two patients had to be excluded from the trial 
after this carefully qualifying process, reflecting good patient selection. Unlike many other 
studies, we repeated the same adherence control at every step of follow-up.  
However, the reliability of witnessed drug intake at a single instance to reflect general drug 
adherence is limited. After a single dose, one does not expect target levels of drug 
concentrations to be reached. Patients who take their medication irregularly, may not achieve 
stable levels of the drugs necessary to treat hypertension, to protect organ damage and 
vasculature changes. Therapeutic drug monitoring, which involves measurements of plasma 
or urine drug or drug metabolite concentrations, is considered a better approach that can 
assess adherence continually. In addition, this may help to personalize the treatment according 
to the patient ‘s individual pharmacokinetic properties. This method may also identify patients 
using drugs other than those prescribed (122, 123). The results from the SPYRAL HTN-ON 
MED trial showed that in 15% of the patients, nonprescribed medication was detected, which 
could not be demonstrated by applying witnessed intake. In the SYMPATHY study, almost 
80% of patients with diagnosed TRH were either poorly adherent or completely nonadherent 
when participants and attending physicians were unaware of the drug measurement (124). In 
addition, about one third of the participants either increased or decreased adherence during 
follow-up, with a trend towards more pills being taken during follow-up. This finding was 
more pronounced in the control group than in the RDN treatment group, which may be 




In the SPYRAL HTN-ON MED study, liquid chromatography mass spectrometry of urine 
and plasma was used in addition to witnessed intake to ensure drug adherence. Even then, 
40% of patients were nonadherent, despite the awareness of compliance control (78). 
However, the ethical aspects in regard to involuntary drug control may be an issue of debate.  
Knowing that a witnessed intake before ABPM could not totally exclude fully or partly 
nonadherent patients, we acknowledge that this was a limitation in our selection of patients 
and that better adherence due to intensive follow-up could contribute to a BP drop after RDN. 
Adequate evaluation of adherence should be an obligatory part of TRH assessment. 
10.4  Study design 
 
The main weaknesses of our study were the nonrandomized design and the lack of control 
group, most preferably a sham procedure treated control group. When a study lacks a control 
group, it is impossible to determine whether the outcomes are attributable to the 
treatment or to other patients’ characteristics and the natural history of the disease (e.g. 
decrease in DBP by age). The effects seen may be wholly or partly due to the intervention 
(RDN) or the placebo effect. Inclusion in a study may increase awareness of the disease, 
adherence to medications and other changes in patient behavior, known as the Hawthorn 
effect (125).  
Another limitation was the sample size. Patients with TRH, but without type 2 diabetes are 
not abundant, so we struggled to find patients that matched our inclusion criteria. However, a 
different study design by reducing a number of drugs from four or more antihypertensive 
drugs to three or more (as recommended in the guidelines) would have enabled us to enroll 
more patients to the group. Although we had sufficient power to detect a significant change in 
IS; the changes in BP measurements and BP indices reduction could be underpowered.  
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The low number of patients limits statistical power and increases the probability of a type 
II error. The low sample size also prevented us from subgroup analyses. In addition, due to 

















  DISCUSSION OF THE MAIN RESULTS 
 
11.1 Blood pressure data 
 
The Re-Shape study was addressed to patients with true TRH, where all possible 
antihypertensive drug classes, as well as lifestyle BP improving factors, had been attempted. 
In 2013, when our patients were included, TRH was defined as office BP> 140/90 mmHg 
despite the use of three or more BP lowering drug classes including a diuretic. Baseline 
characteristics, as reported in paper I, suggested that our patients were optimally treated. The 
mean number of antihypertensive drugs at baseline was 4.8 and all patients used diuretics, 
ARB/ACEI and most of them also spironolactone. 
In paper I, we demonstrated a statistically significant reduction in both office and ambulatory 
SBP and DBP at six-month follow-up despite a decrease in the mean number of 
antihypertensive drugs from 4.8 to 4.2. The results, however, must be interpreted with 
caution. The BP changes from baseline to follow-up may be explained by regression to the 
mean, placebo effect or related to an improved adherence, as mentioned above. The mean 
difference between baseline and six-month follow-up in mean 24-hour SBP was -9 mmHg, 
and 12 out of 23 patients had an SBP drop 5 mmHg, which has been suggested to represent 
treatment response in previous studies (81). However, in SCTs presented by Bhatt et al., 
Desch et al. the mean 24-hour SBP fall in a sham group was -4, -3.5 mmHg, respectively (74, 
126). In the work presented by Weber et al., mean 24-hour SBP reduction in the sham arm 




This is also illustrated in the ReSET study when mean daytime SBP drop in the sham arm was 
zero after one month but then increased to six mmHg at three-month follow-up (128). This 
demonstrates how the placebo and the Hawthorn effects may operate on the results when 
adherence control is not meticulously executed.  
Actually, in our study, we can also observe these non-RDN effects on BP reduction by 
looking at the discrepancy between mean office SBP reduction (-23 mmHg) and mean 24-
hour SBP fall (-9 mmHg). This difference was even higher in the first generation studies (69), 
but quite small in the SCTs as in SPYRAL HTN-OFF/ ON MED and RADIANCE-HTN 
SOLO studies where the mean office SBP reduction compared to mean 24-hour SBP drop 
was 4.5, 0.4,3.8 mmHg, respectively (76-78). 
In paper III we depicted an increase in BP two years after RDN despite an insignificant 
reduction in the total number of antihypertensive medications during follow-up. However, the 
mean number of drugs fell from 4.5 to 4.0 during the two years, which could contribute to a 
BP gain. Rebound in BP may be related to regeneration of renal nerves but also to an increase 
in a nonadherence and an attrition of the Hawthorn effect due to less attention given during 
long follow-up. Additionally, a raise in BP might be associated with later renal vasculature 
complications which were not assessed during follow-up. Finally, a disproportionate effect 
from a few patients on the overall result may always be a possibility in small studies. 
Taking a close look at Figure 8, with individual BP recordings, we can observe wide   
dispersion of the BP fall. Some of the patients experienced huge BP drops, referred before as 
super-responders. Heterogenous response to RDN and its unpredictable effect is a key weak 
point of RDN. Many articles have been published about prediction of responders, however, 
mostly based on studies without sham-controlled group or global registries without adherence 
control of included patients (129).  
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An anatomic phenotype pattern of renal sympathetic nerves, denervation range, depth of 
lesion and finally a contribution of sympathetic nerve overactivity to hypertension, might 
make a difference in the RDN response. Indeed, it appears that RDN lowers BP in selected, 
but not all, patients, possibly due to the different mechanism leading to hypertension. 
However, knowledge in this field is still incomplete, and thus clinically useful 
recommendations for patient selection still have not been made.  
An improvement in peripheral vascular resistance in addition to BP reduction is a potential 
treatment goal to reduce cardiovascular events. Many hypertensive drugs have vasodilator 
effect, and since vasoconstriction is a huge part of SNS activation, RDN may potentially also 
have an effect on vascular resistance. Previous RDN trials reported a drop in BP associated 
with an improved arterial stiffness and a decrease in total peripheral resistance independently 
of change in cardiac output (130, 131). Other RDN studies demonstrated a decrease in PWV 
(132) or improvement of aortic distensibility (133), unrelated to BP reduction. However, none 
of these studies were sham-controlled. The only RDN SCT revealed no significant changes in 
central aortic BP and PWV six months after the procedure in comparison with sham group 
despite significant within-group changes in the RDN group (134). In our study, we sought to 
assess potential changes in arterial stiffness by calculation of PP and AASI – an index 
presented as a negative predictor of BP response after RDN (135). We chose relatively young 
patients to avoid age dependent arterial stiffness. The results from paper III showed unaltered 
PP and AASI during the entire follow up. However, AASI and PP are surrogate indices that 
give limited information compared with PWV. In addition, in paper III we demonstrated a 
significant reduction in MAP during the entire study, however the sham-controlled study by 
Engholm et al. revealed an insignificant MAP reduction between RDN and sham group in 
addition to no improvement in microvascular impairment (136).  
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Thus, not applying a gold standard method for measuring vascular stiffness and not 
preforming SCT with adequate assessment of adherence, one still cannot conclude that RDN 
may improve vascular stiffness. 
Looking at BP results in paper I and III it appears that the BP reduction after RDN was 
significantly more prominent during daytime than night time. In our study, insignificant 
changes were demonstrated for all nocturnal BP variables. Many of patients had nocturnal 
hypertension at baseline and even more at two-year follow-up. Assuming that our patients 
were adequately treated with diuretics, persisting nocturnal hypertension may suggest an 
unbalanced relationship between sympathetic and parasympathetic nervous system, which is 
typical for TRH patients. A possible explanation for the more pronounced effect during 
daytime may be that stress and activity increase SNA, thereby facilitating the RDN treatment 
effect being more pronounced during active hours. Further, SNA reduction occurs 
physiologically during sleep, causing BP reduction during night time to be less available for 
RDN (137). The SCTs have demonstrated conflicting results from a lack of nighttime BP 
drop (126) to a significant fall by -9.8 mmHg in RDN group compared to -2.1 mmHg in the 
sham arm (78). This inconsistency has no clear explanation; it is not unlikely that different 
patient selection criteria, differences in salt ingestion or presence of sleep disturbances may 
affect results. Additionally, the reduced frequency of BP readings during night- or fixed-time 
intervals for ABPM readings, might have affected the calculation of nocturnal BP and 
dipping. A successful reduction in nocturnal BP might have implications for cardiovascular 
endpoints. Growing evidence suggests that nighttime SBP is a stronger predictor for 
cardiovascular events than daytime SBP in hypertensive and diabetic patients (138). Of note, 




In paper I, we looked at other BP parameters that are associated with cardiovascular events, 
such as BPV and morning surge. The transition from sleep to wakefulness is associated with a 
sympathetic activation and a rise in plasma catecholamines, which generally results in an 
increase in BP and heart rate. Another important aspect is that cardiovascular events have 
their greatest prevalence in the early morning period (17). In the current study, both the two-
hour awake and morning BP surge fell significantly six months after RDN. In addition, we 
demonstrated a significant reduction in all indices of BPV (SD, wSD and ARV) both systolic 
and diastolic BP as well as SD of daytime BP, though not SD of nighttime BP.  
The actual clinical value of morning BP surge is still a matter of debate, and conflicting 
results have been obtained (139). The value of BPV variables depends on the sensitivity of 
measurements, dependency on the BP level and high variability among individual patients. 
Thus, our study was too small to conclude about BPV variables, but our results may be 
considered as hypothesis generating. Even though another study with a larger sample size 
revealed improvement in BPV indices six months after RDN (140), none of the SCTs were 









11.2 Metabolic data  
 
Because IR, hypertension and overactivated SNS are closely related, the previously reported 
amelioration of glucose metabolism after RDN has been followed with great interest. IR is 
also associated with polycystic ovary syndrome, nonalcoholic fatty liver disease and psoriasis 
(41), diseases linked to increased SNA, even without hypertension. Therefore, potential 
improvement of IS by RDN may be hypothesized to decrease cardiovascular risk, even in 
these group of patients.  
When including patients to our study, we focused on patients with TRH that had not yet 
developed type 2 diabetes, a disease state with particularly high cardiovascular risk. As it 
turned out, included subjects were modestly obese and had high prediabetes risk. A greater 
part of them had already, before RDN, impaired fasting glucose and hyperinsulinemia, and 
78% of them had metabolic syndrome. When obesity and hypertension are both present in the 
same patient, the degree of SNA is much greater than in those with either condition separately 
(5). Thus, our patients appeared to be a well selected target group for RDN, to improve IS. 
In paper II we presented two steps clamp data to get a closer insight in IS changes. The 
method is considered gold standard method for assessment of IS. Tracer dilution during HEC 
gives the possibility to assess the ability of insulin to suppress EGR. During glucose tracer 
infusion basal EGR and WGD levels were where within normal range and did not change 
after RDN. Calculated EGR reduction from baseline was low and represented high hepatic IR 
before RDN. Six months after RDN we repeated the two-step clamp demonstrating even less 




During step two of the clamp, insulin was infused at a rate that leads to the physiological 
hyperinsulinemia seen after a meal and that effectively increases WGD in individuals with 
normal IS values. The modest increase in WGD with increments in insulin infusion, both at 
baseline and at follow-up, supports the notion that our group of participants also experienced 
severe peripheral IR, which persisted after RDN. A trend toward increased GIR during clamp 
step two after RDN was probably related to the slightly higher serum insulin concentrations 
during clamping at follow-up, as the ISI, which corrects for the prevailing insulin 
concentrations, did not change after RDN. Taken together, our glucose tracer/clamp data did 
not show any change in basal glucose turnover nor improved hepatic or peripheral IS six 
months after RDN. Actually, they were in line with another small uncontrolled clamp study of 
eight nondiabetic patients with severe TRH, published in 2017 by Kampmann et al. (141).  
The effect of the RDN procedure may be hypothesized to appear over a longer time period, 
which is thought to be related to gradually decreasing SNA (113, 142). Although the efferent 
fiber ablation may reduce a sympathetic input to the kidneys fast, the timing of the effect of 
renal sympathetic afferent fiber ablation with consequently remodulation of the central SNA 
may be delayed. Since the long-term effects of central SNA modulation on metabolic changes 
are unknown, we conducted the two-year follow-up.  
Some RDN studies assessed the short effect of RDN on adipokines. It was hypothesized that 
RDN might affect adipokines, given that adipocytes have adrenergic receptors and leptin 
plays a role in the cross-talk between adipose tissue and the central nervous system. Hence, in 
paper III we assessed IR indices two years after RDN and adipokines profile during the entire 
follow-up. Although the included patients were slightly obese, they did not have 
hyperleptinemia, and their mean level of adiponectin was borderline low at baseline. During 
two-year follow-up no changes in their adipokine profiles were registered.  
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As opposed to our findings, other studies exhibited a rise in adiponectin, yet none of them 
demonstrated any change in the leptin level after RDN (143, 144). Differences in the use of 
renin angiotensin aldosterone system (RAAS) inhibitors may be one of the factors explaining 
the opposing study results. In previous studies, an increase in circulating adiponectin after a 
two-month treatment with losartan in hypertensive patients has been reported (145, 146). 
There are other experimental data showing an enhanced adiponectin expression in response to 
long-term use of ARB, and indeed, in our study, all of patients used RAAS inhibitors that 
could diminish the effect of RDN on adipokines (147, 148). 
In paper III we also presented correlations between IS assessed by the gold standard clamp 
method and commonly used IR surrogate indices. In previous non-RDN metabolic trials, 
HOMA-IR was thought to represent hepatic IR and could possibly underestimate peripheral 
IR (149, 150). In our research HOMA-IR correlated best with total IS, whereas OGTT 30min 
correlated best with hepatic IR. These variations in results may have been caused by assessing 
different groups of patients representing different kinds of IR. This emphasize the need for the 
gold standard method when evaluating IS in selected groups of patients.    
Collectively, in paper II and III, both clamp measurements and surrogate indices confirmed 
that our patients had severe IR before RDN, with no improvements in IS after short- and long-
term follow-up. Rather, a smaller reduction in EGR during the low-dose insulin clamp at 
follow-up was seen, suggesting deterioration of hepatic IR.  
After two years, most of the surrogate indices tended to be higher, although only HOMA-AD 
demonstrated a significant worsening in IS. Knowing that our results showed only modest 
correlations between clamp data and surrogate indices, we cannot exclude that performing a 




To our knowledge, our study is by far the largest assessing IS using the time consuming and 
cumbersome gold standard method in TRH patients undergoing RDN. Therefore, comparison 
of our results with other studies is currently limited. Some small uncontrolled metabolic RDN 
human trials showed contradictory results. Even though the inconsistency cannot be easily 
explained, the use of different IR indices, RDN devices and inclusion criteria might be the 
reasons. Additionally, an absence of adherence control of both antihypertensive and 
antidiabetic drugs makes these studies difficult to interpret. Even more, no RDN SCT 
focusing on metabolic changes has been published until now; thus, the hypothesis that RDN 













  MAIN CONCLUSIONS 
 
The main hypothesis of this research was, that a decrease in SNA may improve IS in patients 
with TRH. Additionally, one expected an amelioration of BP indices. The study assumed that 
RDN is a method able to modulate SNA.  
The results of our study do not support the hypothesis that RDN leads to beneficial metabolic 
effects or can alleviate IR in patients with long-term TRH, providing that the RDN procedure 
was successful. Knowing the unpredictable degree of denervation, negative metabolic results 
may represent an ineffective procedure or the resistance of IS improvement by SNA 
modulation in patients with TRH.  
Thus, the hypothesis has not been resolved by this study. Whether autonomic nerve system 
modulation may ameliorate peripheral IR by decreasing vasoconstriction in advanced stage 
hypertensive patients with vascular changes, has not yet been settled. To what extent devices 
may decrease SNA to improve metabolism in overworked adipose tissue, is another 
conundrum. Finally, there is vagueness concerning whether this perturbed autonomic nervous 
system function in severely hypertensive patients may be reversible at all, of any device 







12.1 Paper I 
 
The results of this study demonstrated a statistically significant reduction in office and ABPM 
six months after RDN. In addition, we observed decreases in all BPV indices apart from 
nocturnal BPV. The RDN procedure was done without any major adverse effects. However, 
due to the absence of a sham-controlled group and lack of meticulously adherence 
assessment, we cannot conclude whether the observed BP changes were related to 
denervation or other factors.   
12.2 Paper II 
 
Neither peripheral nor hepatic IS improved six months after the RDN treatment in this group 
of insulin resistant patients without diabetes and with TRH, as measured with gold standard 
methods, “two steps HEC”. However, due to the study design, we could not justify whether a 
lack of IS improvement was related to resistance towards SNA alterations or reflect only that 
RDN was not enough effective to modulate SNA. 
12.3 Paper III   
 
Two years after RDN, IS and parameters of glucose metabolism had not improved. The 
limited accuracy of several IR surrogate indices, compared to HEC, was demonstrated in this 
well-defined group of patients. There were no correlations between the magnitude of IR prior 
to RDN and BP changes. Patients with higher nocturnal SBP and arterial stiffness presented a 




 FURTHER RESEARCH 
 
RDN research has gone through major enthusiasm and flames during the last ten years. Much 
has been learnt from RDN studies about the importance of adherence, BP measurements and 
careful selection of patient with uncontrolled hypertension. Negative results forced scientists 
to broaden their knowledge of renal artery microanatomy and to improve RDN devices.  
Learning from older RDN research, new proof-of-concept studies were performed, showing 
BP reduction, however still quite small and not superior to well-adjusted antihypertensive 
drug treatment. Is it the end of the road for RDN? What about the patients who struggle with 
adherence? What about the patient’s preference? Is the idea of moving RDN from TRH to 
younger patients with mild hypertension the right way to go? The aspects of adherence, 
quality of life due to polypharmacy and potential impact of RDN on heart failure, kidney 
function, arrhythmias, IR and other consequences of increased SNA may be issues bringing 
RDN further in the clinical world. Nowadays, RDN is not recommended in clinical practice 
guidelines. Concerns, such as the target group for RDN treatment, device type, control of 
denervation effectiveness, and diagnostic systems for renal nerves mapping are each and all 
issues yet to be resolved. In spite of this, the setbacks of RDN should not decrease the interest 
for research in a device technology aiming to modulate SNA. These are all complex issues, 
and high-quality, investigator-initiated research is needed to understand the potential of new 
device-based technologies to modulate SNA, especially in conditions as IR, where effects of 
medical treatment and lifestyle changes is difficult to achieve. Improvement in IS may be a 
key factor to protect against type 2 diabetes development, and thus decreases cardiovascular 
risk. None of the RDN trials was designed to look at hard clinical end points as primary 
outcomes. Such results are warranted before getting SNA modulating devices into routine 
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